<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28804170</article-id><article-id pub-id-type="pmc">5537756</article-id><article-id pub-id-type="publisher-id">BLT.17.193375</article-id><article-id pub-id-type="doi">10.2471/BLT.17.193375</article-id><article-categories><subj-group subj-group-type="heading"><subject>Systematic Reviews</subject></subj-group></article-categories><title-group><article-title>Decentralized care for multidrug-resistant tuberculosis: a systematic review and meta-analysis</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">Prise en charge d&#x000e9;centralis&#x000e9;e de la tuberculose multir&#x000e9;sistante: revue syst&#x000e9;matique et m&#x000e9;ta-analyse</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">Atenci&#x000f3;n descentralizada para la tuberculosis multirresistente: una revisi&#x000f3;n sistem&#x000e1;tica y un metaan&#x000e1;lisis</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar">&#x00627;&#x00644;&#x00631;&#x00639;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00644;&#x00627;&#x00645;&#x00631;&#x00643;&#x00632;&#x0064a;&#x00629; &#x00644;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00644; &#x00627;&#x00644;&#x00645;&#x00642;&#x00627;&#x00648;&#x00645; &#x00644;&#x00644;&#x00623;&#x0062f;&#x00648;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00639;&#x0062f;&#x0062f;&#x00629;: <bold/>&#x00645;&#x00631;&#x00627;&#x0062c;&#x00639;&#x00629;&#x000a0;&#x00645;&#x00646;&#x00647;&#x0062c;&#x0064a;&#x00629; &#x00648;&#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644;&#x000a0;&#x0062a;&#x0064e;&#x00644;&#x00648;&#x0064a; </trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title xml:lang="zh">&#x08010;&#x0591a;&#x0836f;&#x07ed3;&#x06838;&#x075c5;&#x05206;&#x06563;&#x05316;&#x062a4;&#x07406;&#x0ff1a; &#x07cfb;&#x07edf;&#x08bc4;&#x05ba1;&#x0548c;&#x05143;&#x05206;&#x06790;</trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">&#x00414;&#x00435;&#x00446;&#x00435;&#x0043d;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x00430;&#x0044f; &#x00444;&#x0043e;&#x00440;&#x0043c;&#x00430; &#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x0043c;&#x00435;&#x00434;&#x00438;&#x00446;&#x00438;&#x0043d;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00449;&#x00438; &#x0043f;&#x00440;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x00435; &#x00441;&#x0043e; &#x0043c;&#x0043d;&#x0043e;&#x00436;&#x00435;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x0043b;&#x00435;&#x0043a;&#x00430;&#x00440;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x00443;&#x00441;&#x00442;&#x0043e;&#x00439;&#x00447;&#x00438;&#x00432;&#x0043e;&#x00441;&#x00442;&#x0044c;&#x0044e;: &#x00441;&#x00438;&#x00441;&#x00442;&#x00435;&#x0043c;&#x00430;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00439; &#x0043e;&#x00431;&#x00437;&#x0043e;&#x00440; &#x00438; &#x0043c;&#x00435;&#x00442;&#x00430;&#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">Jennifer Ho et al.</alt-title><alt-title alt-title-type="title-running-head">Decentralized care for multidrug-resistant tuberculosis</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ho</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Byrne</surname><given-names>Anthony L</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Linh</surname><given-names>Nguyen N</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jaramillo</surname><given-names>Ernesto</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fox</surname><given-names>Greg J</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><aff id="aff1"><label>a</label>Woolcock Institute of Medical Research, University of Sydney, 431 Glebe Point Road, Glebe, New South Wales 2037, <country>Australia</country>.</aff><aff id="aff2"><label>b</label>Global TB Programme, World Health Organization, Geneva, <country>Switzerland</country>.</aff><aff id="aff3"><label>c</label>Central Clinical School, University of Sydney, Sydney, <country>Australia</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to Jennifer Ho (email: <email xlink:href="jennifer.ho@sydney.edu.au">jennifer.ho@sydney.edu.au</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>8</month><year>2017</year></pub-date><volume>95</volume><issue>8</issue><fpage>584</fpage><lpage>593</lpage><history><date date-type="received"><day>04</day><month>3</month><year>2017</year></date><date date-type="rev-recd"><day>10</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>22</day><month>5</month><year>2017</year></date><date><day>09</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>(c) 2017 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>To assess the effectiveness of decentralized treatment and care for patients with multidrug-resistant (MDR) tuberculosis, in comparison with centralized approaches.</p></sec><sec><title>Methods</title><p>We searched ClinicalTrials.gov, the Cochrane library, Embase&#x000ae;, Google Scholar, LILACS, PubMed&#x000ae;, Web of Science and the World Health Organization&#x02019;s portal of clinical trials for studies reporting treatment outcomes for decentralized and centralized care of MDR tuberculosis. The primary outcome was treatment success. When possible, we also evaluated, death, loss to follow-up, treatment adherence and health-system costs. To obtain pooled relative risk (RR) estimates, we performed random-effects meta-analyses.</p></sec><sec><title>Findings</title><p>Eight studies met the eligibility criteria for review inclusion. Six cohort studies, with 4026 participants in total, reported on treatment outcomes. The pooled RR estimate for decentralized versus centralized care for treatment success was 1.13 (95% CI: 1.01&#x02013;1.27). The corresponding estimate for loss to follow-up was RR: 0.66 (95% CI: 0.38&#x02013;1.13), for death RR: 1.01 (95% CI: 0.67&#x02013;1.52) and for treatment failure was RR: 1.07 (95% CI: 0.48&#x02013;2.40). Two of three studies evaluating health-care costs reported lower costs for the decentralized models of care than for the centralized models.</p></sec><sec><title>Conclusion</title><p>Treatment success was more likely among patients with MDR tuberculosis treated using a decentralized approach. Further studies are required to explore the effectiveness of decentralized MDR tuberculosis care in a range of different settings.</p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9;</title><sec><title>Objectif</title><p>&#x000c9;valuer l'efficacit&#x000e9; de la prise en charge et des traitements d&#x000e9;centralis&#x000e9;s pour les patients atteints de tuberculose multir&#x000e9;sistante (TB-MR), par rapport aux approches centralis&#x000e9;es.</p></sec><sec><title>M&#x000e9;thodes</title><p>Nous avons recherch&#x000e9;, dans les bases de donn&#x000e9;es de ClinicalTrials.gov, de la Cochrane Library, d'Embase&#x000ae;, de Google Scholar, de LILACS, de PubMed&#x000ae; et de Web of Science, ainsi que sur le portail de l'Organisation mondiale de la Sant&#x000e9; d&#x000e9;di&#x000e9; aux essais cliniques, des &#x000e9;tudes qui mentionnaient les r&#x000e9;sultats d&#x02019;une prise en charge centralis&#x000e9;e ou d&#x000e9;centralis&#x000e9;e de la tuberculose multir&#x000e9;sistante. Le premier crit&#x000e8;re pris en compte &#x000e9;tait la r&#x000e9;ussite du traitement. Lorsque cela &#x000e9;tait possible, nous avons aussi &#x000e9;valu&#x000e9; le nombre de d&#x000e9;c&#x000e8;s, l'interruption du suivi, le respect du traitement et les co&#x000fb;ts pour le syst&#x000e8;me de sant&#x000e9;. Afin d'obtenir des estimations globales du risque relatif (RR), nous avons proc&#x000e9;d&#x000e9; &#x000e0; des m&#x000e9;ta-analyses &#x000e0; effets al&#x000e9;atoires.</p></sec><sec><title>R&#x000e9;sultats</title><p>Huit &#x000e9;tudes remplissaient les crit&#x000e8;res d'admissibilit&#x000e9; permettant d'&#x000ea;tre incluses dans notre revue. Six &#x000e9;tudes de cohortes, comportant 4026&#x000a0;participants au total, mentionnaient les r&#x000e9;sultats de traitements. L'estimation globale du RR d'une prise en charge d&#x000e9;centralis&#x000e9;e par rapport &#x000e0; une prise en charge centralis&#x000e9;e concernant la r&#x000e9;ussite du traitement &#x000e9;tait de 1,13 (IC 95%: 1,01-1,27). Les estimations correspondantes du RR &#x000e9;taient, pour l'interruption du suivi, de 0,66 (IC 95%: 0,38&#x02013;1,13), pour le d&#x000e9;c&#x000e8;s: 1,01 (IC 95%: 0,67&#x02013;1,52) et pour l'&#x000e9;chec du traitement: 1,07 (IC 95%: 0,48-2,40). Deux &#x000e9;tudes sur trois qui &#x000e9;valuaient les co&#x000fb;ts pour le syst&#x000e8;me de sant&#x000e9; ont fait &#x000e9;tat de co&#x000fb;ts plus faibles pour les mod&#x000e8;les d&#x000e9;centralis&#x000e9;s que pour les mod&#x000e8;les centralis&#x000e9;s.</p></sec><sec><title>Conclusion</title><p>Les traitements avaient plus de chances de r&#x000e9;ussir chez les patients atteints de tuberculose multir&#x000e9;sistante trait&#x000e9;s selon une approche d&#x000e9;centralis&#x000e9;e. D'autres &#x000e9;tudes sont n&#x000e9;cessaires pour &#x000e9;valuer l'efficacit&#x000e9; de la prise en charge d&#x000e9;centralis&#x000e9;e de la tuberculose multir&#x000e9;sistante dans une diversit&#x000e9; de contextes.<bold/></p></sec></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><sec><title>Objetivo</title><p>Evaluar la efectividad de la atenci&#x000f3;n y el tratamiento descentralizados para pacientes con tuberculosis multirresistente (TB-MR), en comparaci&#x000f3;n con los enfoques centralizados.</p></sec><sec><title>M&#x000e9;todos</title><p>Se realizaron b&#x000fa;squedas de estudios que informen sobre resultados de tratamientos para la TB-MR con atenci&#x000f3;n descentralizada y centralizada en ClinicalTrials.gov, la Biblioteca Cochrane, Embase&#x000ae;, Google Scholar, LILACS, PubMed&#x000ae;, Web of Science y el portal de ensayos cl&#x000ed;nicos de la Organizaci&#x000f3;n Mundial de la Salud. El resultado principal era el &#x000e9;xito del tratamiento. Cuando fue posible, tambi&#x000e9;n se tuvieron en consideraci&#x000f3;n las defunciones, las p&#x000e9;rdidas durante el seguimiento, el cumplimiento del tratamiento y los costes del sistema sanitario. Para obtener estimaciones de riesgo relativo (RR) combinadas, se realizaron metaan&#x000e1;lisis de efectos aleatorios.</p></sec><sec><title>Resultados</title><p>Ocho estudios cumplieron con los criterios de elegibilidad para incluirse en la revisi&#x000f3;n. Seis estudios de cohortes, con 4&#x000a0;026 participantes en total, contribuyeron con los resultados del tratamiento. La estimaci&#x000f3;n de RR combinada de la atenci&#x000f3;n descentralizada frente a la centralizada para el &#x000e9;xito del tratamiento fue de 1,13 (IC del 95%: 1,01&#x02013;1,27). Las estimaciones correspondientes para las p&#x000e9;rdidas durante el seguimiento tuvieron un RR de 0,66 (IC del 95%: 0,38&#x02013;1,13), el RR de las defunciones fue de 1,01 (IC del 95%: 0,67&#x02013;1,52) y el RR del incumplimiento del tratamiento fue de 1,07 (IC del 95%: 0,48&#x02013;2,40). Dos de tres estudios que evaluaban los costes de la atenci&#x000f3;n sanitaria registraron menos costes para los modelos de atenci&#x000f3;n descentralizada que para los modelos centralizados.</p></sec><sec><title>Conclusi&#x000f3;n</title><p>El &#x000e9;xito del tratamiento era m&#x000e1;s probable entre pacientes con TB-MR tratada con un enfoque descentralizado. Los estudios adicionales necesitan explorar la efectividad de la atenci&#x000f3;n descentralizada de la TB-MR en una variedad de distintos contextos.</p></sec></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><sec><title>&#x00627;&#x00644;&#x0063a;&#x00631;&#x00636; </title><p>&#x0062a;&#x00642;&#x0064a;&#x0064a;&#x00645; &#x00641;&#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00627;&#x00644;&#x00644;&#x00627;&#x00645;&#x00631;&#x00643;&#x00632;&#x0064a; &#x00648;&#x00631;&#x00639;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00631;&#x00636;&#x00649; &#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x0064a;&#x00639;&#x00627;&#x00646;&#x00648;&#x00646; &#x00645;&#x00646; &#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00644; &#x00627;&#x00644;&#x00645;&#x00642;&#x00627;&#x00648;&#x00645; &#x00644;&#x00644;&#x00623;&#x0062f;&#x00648;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00639;&#x0062f;&#x0062f;&#x00629; (MDR)&#x0060c; &#x00628;&#x00627;&#x00644;&#x00645;&#x00642;&#x00627;&#x00631;&#x00646;&#x00629; &#x00645;&#x00639; &#x00627;&#x00644;&#x00623;&#x00633;&#x00627;&#x00644;&#x0064a;&#x00628; &#x00627;&#x00644;&#x00645;&#x00631;&#x00643;&#x00632;&#x0064a;&#x00629;. </p></sec><sec><title>&#x00627;&#x00644;&#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; </title><p>&#x00642;&#x00645;&#x00646;&#x00627; &#x00628;&#x00627;&#x00644;&#x00628;&#x0062d;&#x0062b; &#x00641;&#x0064a; ClinicalTrials.gov&#x0060c; &#x00648;&#x00645;&#x00643;&#x0062a;&#x00628;&#x00629; Cochrane&#x0060c; &#x00648;Embase&#x000ae;&#x0200e;&#x0060c; &#x00648;Google Scholar&#x0060c; &#x00648;LILACS&#x0060c; &#x00648;PubMed&#x000ae;&#x0200e;&#x0060c; &#x00648;Web of Science &#x00648;&#x00627;&#x00644;&#x00628;&#x00648;&#x00627;&#x00628;&#x00629; &#x00627;&#x00644;&#x00625;&#x00644;&#x00643;&#x0062a;&#x00631;&#x00648;&#x00646;&#x0064a;&#x00629; &#x00644;&#x00645;&#x00646;&#x00638;&#x00645;&#x00629; &#x00627;&#x00644;&#x00635;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00639;&#x00627;&#x00644;&#x00645;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062e;&#x00627;&#x00635;&#x00629; &#x00628;&#x00627;&#x00644;&#x0062a;&#x0062c;&#x00627;&#x00631;&#x00628; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00631;&#x0064a;&#x00629; &#x00639;&#x00646; &#x0062f;&#x00631;&#x00627;&#x00633;&#x00627;&#x0062a; &#x00625;&#x00628;&#x00644;&#x00627;&#x0063a; &#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; &#x00639;&#x00644;&#x00627;&#x0062c; &#x00627;&#x00644;&#x00631;&#x00639;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00644;&#x00627;&#x00645;&#x00631;&#x00643;&#x00632;&#x0064a;&#x00629; &#x00648;&#x00627;&#x00644;&#x00645;&#x00631;&#x00643;&#x00632;&#x0064a;&#x00629; &#x00644;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00644; &#x00627;&#x00644;&#x00645;&#x00642;&#x00627;&#x00648;&#x00645; &#x00644;&#x00644;&#x00623;&#x0062f;&#x00648;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00639;&#x0062f;&#x0062f;&#x00629;. &#x00648;&#x00623;&#x00638;&#x00647;&#x00631;&#x0062a; &#x00627;&#x00644;&#x00646;&#x0062a;&#x0064a;&#x0062c;&#x00629; &#x00627;&#x00644;&#x00623;&#x00648;&#x00644;&#x0064a;&#x00629; &#x00646;&#x0062c;&#x00627;&#x0062d; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c;. &#x00643;&#x00645;&#x00627; &#x00642;&#x00645;&#x00646;&#x00627; &#x00628;&#x0062a;&#x00642;&#x0064a;&#x0064a;&#x00645; &#x00627;&#x00644;&#x00648;&#x00641;&#x0064a;&#x00627;&#x0062a;&#x0060c; &#x00648;&#x00641;&#x00642;&#x0062f;&#x00627;&#x00646; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00627;&#x00628;&#x00639;&#x00629;&#x0060c; &#x00648;&#x00627;&#x00644;&#x00627;&#x00644;&#x0062a;&#x00632;&#x00627;&#x00645; &#x00628;&#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c;&#x0060c; &#x00648;&#x0062a;&#x00643;&#x00627;&#x00644;&#x0064a;&#x00641; &#x00627;&#x00644;&#x00646;&#x00638;&#x00627;&#x00645; &#x00627;&#x00644;&#x00635;&#x0062d;&#x0064a; &#x00639;&#x00646;&#x0062f;&#x00645;&#x00627; &#x00643;&#x00627;&#x00646; &#x00630;&#x00644;&#x00643; &#x00645;&#x00645;&#x00643;&#x00646;&#x0064b;&#x00627;. &#x00648;&#x00644;&#x00644;&#x0062d;&#x00635;&#x00648;&#x00644; &#x00639;&#x00644;&#x00649; &#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00637;&#x00627;&#x00631; &#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x0064a; &#x00627;&#x00644;&#x00645;&#x0062c;&#x00645;&#x00639;&#x00629; (RR)&#x0060c; &#x00623;&#x0062c;&#x00631;&#x0064a;&#x00646;&#x00627; &#x0062a;&#x0062d;&#x00627;&#x00644;&#x0064a;&#x00644; &#x0062a;&#x00644;&#x00648;&#x0064a;&#x00629; &#x00639;&#x00634;&#x00648;&#x00627;&#x00626;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062a;&#x00623;&#x0062b;&#x0064a;&#x00631;&#x00627;&#x0062a;. </p></sec><sec><title>&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; </title><p>&#x00627;&#x00633;&#x0062a;&#x00648;&#x00641;&#x0062a; &#x0062b;&#x00645;&#x00627;&#x00646;&#x0064a; &#x0062f;&#x00631;&#x00627;&#x00633;&#x00627;&#x0062a; &#x00645;&#x00639;&#x00627;&#x0064a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00623;&#x00647;&#x00644;&#x0064a;&#x00629; &#x00644;&#x00625;&#x0062f;&#x00631;&#x00627;&#x0062c;&#x00647;&#x00627; &#x00641;&#x0064a; &#x00639;&#x00645;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00631;&#x00627;&#x0062c;&#x00639;&#x00629;. &#x00648;&#x00642;&#x0062f; &#x00623;&#x00648;&#x00631;&#x0062f;&#x0062a; &#x00633;&#x0062a; &#x0062f;&#x00631;&#x00627;&#x00633;&#x00627;&#x0062a; &#x00623;&#x0062a;&#x00631;&#x00627;&#x00628;&#x0064a;&#x00629; &#x00639;&#x00646; &#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00648;&#x00627;&#x00644;&#x0062a;&#x0064a; &#x00636;&#x00645;&#x0062a; 4026 &#x00645;&#x00634;&#x00627;&#x00631;&#x00643;&#x0064b;&#x00627; &#x00628;&#x00634;&#x00643;&#x00644; &#x00625;&#x0062c;&#x00645;&#x00627;&#x00644;&#x0064a;. &#x00648;&#x00643;&#x00627;&#x00646;&#x0062a; &#x00646;&#x00633;&#x00628;&#x00629; &#x00646;&#x0062c;&#x00627;&#x0062d; &#x00639;&#x00644;&#x00627;&#x0062c; &#x00627;&#x00644;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00645;&#x0062c;&#x00645;&#x00639; &#x00644;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00637;&#x00627;&#x00631; &#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x0064a; &#x00645;&#x00646; &#x00623;&#x0062c;&#x00644; &#x00627;&#x00644;&#x00631;&#x00639;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00644;&#x00627;&#x00645;&#x00631;&#x00643;&#x00632;&#x0064a;&#x00629; &#x00645;&#x00642;&#x00627;&#x00628;&#x00644; &#x00627;&#x00644;&#x00631;&#x00639;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00631;&#x00643;&#x00632;&#x0064a;&#x00629; 1.13 (&#x00628;&#x00646;&#x00633;&#x00628;&#x00629; &#x00623;&#x00631;&#x0062c;&#x0062d;&#x0064a;&#x00629; &#x00645;&#x00642;&#x0062f;&#x00627;&#x00631;&#x00647;&#x00627; <styled-content style-type="direction" style="direction:ltr;">95&#x0200f;%</styled-content>: 1.01&#x02013;1.27). &#x00648;&#x00643;&#x00627;&#x00646;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x00642;&#x00627;&#x00628;&#x00644;&#x00629; &#x00644;&#x00641;&#x00642;&#x0062f;&#x00627;&#x00646; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00627;&#x00628;&#x00639;&#x00629; &#x00647;&#x0064a; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00637;&#x00627;&#x00631; &#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x0064a;: 0.66 (&#x00628;&#x00646;&#x00633;&#x00628;&#x00629; &#x00623;&#x00631;&#x0062c;&#x0062d;&#x0064a;&#x00629; &#x00645;&#x00642;&#x0062f;&#x00627;&#x00631;&#x00647;&#x00627; <styled-content style-type="direction" style="direction:ltr;">95&#x0200f;%</styled-content>: 0.38&#x0200f;-1.13)&#x0060c; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00637;&#x00627;&#x00631; &#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x0064a; &#x00644;&#x00644;&#x00648;&#x00641;&#x0064a;&#x00627;&#x0062a;: 1.01 (&#x00628;&#x00646;&#x00633;&#x00628;&#x00629; &#x00623;&#x00631;&#x0062c;&#x0062d;&#x0064a;&#x00629; &#x00645;&#x00642;&#x0062f;&#x00627;&#x00631;&#x00647;&#x00627; <styled-content style-type="direction" style="direction:ltr;">95&#x0200f;%</styled-content>: 0.67&#x0200f;-1.52) &#x00648;&#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00644;&#x00641;&#x00634;&#x00644; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00643;&#x00627;&#x00646; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00637;&#x00627;&#x00631; &#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x0064a;: 1.07 (&#x00628;&#x00646;&#x00633;&#x00628;&#x00629; &#x00623;&#x00631;&#x0062c;&#x0062d;&#x0064a;&#x00629; &#x00645;&#x00642;&#x0062f;&#x00627;&#x00631;&#x00647;&#x00627; <styled-content style-type="direction" style="direction:ltr;">95%</styled-content>: 0.48&#x0200f;-2.40). &#x00623;&#x00648;&#x00631;&#x0062f;&#x0062a; &#x00627;&#x0062b;&#x00646;&#x0062a;&#x00627;&#x00646; &#x00645;&#x00646; &#x00636;&#x00645;&#x00646; &#x0062b;&#x00644;&#x00627;&#x0062b; &#x0062f;&#x00631;&#x00627;&#x00633;&#x00627;&#x0062a; &#x00644;&#x0062a;&#x00642;&#x0064a;&#x0064a;&#x00645; &#x0062a;&#x00643;&#x00627;&#x00644;&#x0064a;&#x00641; &#x00627;&#x00644;&#x00631;&#x00639;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00635;&#x0062d;&#x0064a;&#x00629; &#x00639;&#x00646; &#x00627;&#x00646;&#x0062e;&#x00641;&#x00627;&#x00636; &#x0062a;&#x00643;&#x00627;&#x00644;&#x0064a;&#x00641; &#x00646;&#x00645;&#x00627;&#x00630;&#x0062c; &#x00627;&#x00644;&#x00631;&#x00639;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00644;&#x00627;&#x00645;&#x00631;&#x00643;&#x00632;&#x0064a;&#x00629; &#x00639;&#x00646; &#x00627;&#x00644;&#x00646;&#x00645;&#x00627;&#x00630;&#x0062c; &#x00627;&#x00644;&#x00645;&#x00631;&#x00643;&#x00632;&#x0064a;&#x00629;. </p></sec><sec><title>&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; </title><p>&#x00643;&#x00627;&#x00646; &#x00646;&#x0062c;&#x00627;&#x0062d; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00623;&#x00643;&#x0062b;&#x00631; &#x00627;&#x0062d;&#x0062a;&#x00645;&#x00627;&#x00644;&#x0064b;&#x00627; &#x00628;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00645;&#x00631;&#x00636;&#x00649; &#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x0064a;&#x00639;&#x00627;&#x00646;&#x00648;&#x00646; &#x00645;&#x00646; &#x00627;&#x00644;&#x00633;&#x00644; &#x00627;&#x00644;&#x00645;&#x00642;&#x00627;&#x00648;&#x00645; &#x00644;&#x00644;&#x00623;&#x0062f;&#x00648;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00639;&#x0062f;&#x0062f;&#x00629; &#x00648;&#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x0062a;&#x00645; &#x00639;&#x00644;&#x00627;&#x0062c;&#x00647;&#x00645; &#x00628;&#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x00623;&#x00633;&#x00644;&#x00648;&#x00628; &#x00644;&#x00627;&#x00645;&#x00631;&#x00643;&#x00632;&#x0064a;. &#x0064a;&#x00644;&#x00632;&#x00645; &#x00625;&#x0062c;&#x00631;&#x00627;&#x00621; &#x00645;&#x00632;&#x0064a;&#x0062f; &#x00645;&#x00646; &#x00627;&#x00644;&#x0062f;&#x00631;&#x00627;&#x00633;&#x00627;&#x0062a; &#x00644;&#x00627;&#x00633;&#x0062a;&#x00643;&#x00634;&#x00627;&#x00641; &#x00641;&#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00631;&#x00639;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00644;&#x00627;&#x00645;&#x00631;&#x00643;&#x00632;&#x0064a;&#x00629; &#x00644;&#x00644;&#x00633;&#x00644; &#x00627;&#x00644;&#x00645;&#x00642;&#x00627;&#x00648;&#x00645; &#x00644;&#x00644;&#x00623;&#x0062f;&#x00648;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00639;&#x0062f;&#x0062f;&#x00629; (MDR) &#x00641;&#x0064a; &#x00645;&#x0062c;&#x00645;&#x00648;&#x00639;&#x00629; &#x00645;&#x00646; &#x00627;&#x00644;&#x00628;&#x0064a;&#x00626;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x0062e;&#x0062a;&#x00644;&#x00641;&#x00629;. <bold/></p></sec></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><sec><title>&#x076ee;&#x07684;</title><p>&#x05bf9;&#x06bd4;&#x096c6;&#x04e2d;&#x06cbb;&#x07597;&#x065b9;&#x06cd5;&#x08bc4;&#x04f30;&#x08010;&#x0591a;&#x0836f;&#x07ed3;&#x06838;&#x075c5;&#x000a0;(MDR)&#x000a0;&#x060a3;&#x08005;&#x07684;&#x05206;&#x06563;&#x05316;&#x06cbb;&#x07597;&#x0548c;&#x062a4;&#x07406;&#x07684;&#x06548;&#x0679c;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>&#x06211;&#x04eec;&#x0641c;&#x07d22;&#x04e86;&#x000a0;ClinicalTrials.gov&#x03001;Cochrane&#x000a0;&#x056fe;&#x04e66;&#x09986;&#x03001;Embase&#x000ae;&#x03001;&#x08c37;&#x06b4c;&#x05b66;&#x0672f;&#x03001;LILACS&#x03001;PubMed&#x000ae;&#x03001;Web of Science&#x000a0;&#x0548c;&#x04e16;&#x0754c;&#x0536b;&#x0751f;&#x07ec4;&#x07ec7;&#x04e34;&#x05e8a;&#x08bd5;&#x09a8c;&#x095e8;&#x06237;&#x07f51;&#x07ad9;&#x04e0a;&#x06709;&#x05173;&#x08010;&#x0591a;&#x0836f;&#x07ed3;&#x06838;&#x075c5;&#x000a0;(MDR)&#x000a0;&#x060a3;&#x08005;&#x07684;&#x05206;&#x06563;&#x05316;&#x0548c;&#x096c6;&#x04e2d;&#x06cbb;&#x07597;&#x07ed3;&#x0679c;&#x07684;&#x07814;&#x07a76;&#x03002; &#x04e3b;&#x08981;&#x07684;&#x06210;&#x0679c;&#x0662f;&#x06cbb;&#x07597;&#x06210;&#x0529f;&#x03002; &#x06761;&#x04ef6;&#x05141;&#x08bb8;&#x065f6;&#x0ff0c;&#x06211;&#x04eec;&#x08fd8;&#x05bf9;&#x06b7b;&#x04ea1;&#x07387;&#x03001;&#x05931;&#x08bbf;&#x07387;&#x03001;&#x06cbb;&#x07597;&#x04f9d;&#x04ece;&#x06027;&#x0548c;&#x0536b;&#x0751f;&#x07cfb;&#x07edf;&#x06210;&#x0672c;&#x08fdb;&#x0884c;&#x04e86;&#x08bc4;&#x04f30;&#x03002; &#x04e3a;&#x04e86;&#x083b7;&#x053d6;&#x06c47;&#x0603b;&#x076f8;&#x05bf9;&#x098ce;&#x09669;&#x000a0;(RR)&#x000a0;&#x04f30;&#x0503c;&#x0ff0c;&#x06211;&#x04eec;&#x08fdb;&#x0884c;&#x04e86;&#x0968f;&#x0673a;&#x06548;&#x05e94;&#x05143;&#x05206;&#x06790;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x0516b;&#x09879;&#x07814;&#x07a76;&#x07b26;&#x05408;&#x07eb3;&#x05165;&#x08bc4;&#x05ba1;&#x07684;&#x08d44;&#x0683c;&#x06807;&#x051c6;&#x03002; &#x05171;&#x06709;&#x000a0;4026&#x000a0;&#x0540d;&#x053c2;&#x04e0e;&#x08005;&#x053c2;&#x04e0e;&#x04e86;&#x0516d;&#x09879;&#x0961f;&#x05217;&#x07814;&#x07a76;&#x0ff0c;&#x062a5;&#x0544a;&#x04e86;&#x06cbb;&#x07597;&#x07ed3;&#x0679c;&#x03002; &#x06cbb;&#x07597;&#x06210;&#x0529f;&#x07684;&#x05206;&#x06563;&#x05316;&#x0548c;&#x096c6;&#x04e2d;&#x062a4;&#x07406;&#x07684;&#x06c47;&#x0603b;&#x000a0;RR&#x000a0;&#x04f30;&#x0503c;&#x04e3a;&#x000a0;1.13&#x000a0;(95% CI: 1.01&#x02013;1.27)&#x03002; &#x076f8;&#x05e94;&#x07684;&#x05931;&#x08bbf;&#x07387;&#x000a0;RR&#x000a0;&#x04f30;&#x0503c;&#x04e3a;&#x0ff1a; 0.66&#x000a0;(95% CI: 0.38&#x02013;1.13)&#x0ff0c;&#x06b7b;&#x04ea1;&#x07387;&#x000a0;RR&#x000a0;&#x04f30;&#x0503c;&#x04e3a;&#x0ff1a; 1.01&#x000a0;(95% CI: 0.67&#x02013;1.52)&#x0ff0c;&#x06cbb;&#x07597;&#x05931;&#x08d25;&#x000a0;RR&#x000a0;&#x04f30;&#x0503c;&#x04e3a;&#x0ff1a; 1.07&#x000a0;(95% CI: 0.48&#x02013;2.40)&#x03002; &#x04e09;&#x04efd;&#x08bc4;&#x04f30;&#x0533b;&#x07597;&#x062a4;&#x07406;&#x06210;&#x0672c;&#x07684;&#x07814;&#x07a76;&#x04e2d;&#x0ff0c;&#x06709;&#x04e24;&#x09879;&#x06307;&#x051fa;&#x0ff0c;&#x05206;&#x06563;&#x06a21;&#x05f0f;&#x07684;&#x062a4;&#x07406;&#x06210;&#x0672c;&#x04f4e;&#x04e8e;&#x096c6;&#x04e2d;&#x06a21;&#x05f0f;&#x07684;&#x06210;&#x0672c;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x091c7;&#x07528;&#x05206;&#x06563;&#x05316;&#x065b9;&#x06cd5;&#x08fdb;&#x0884c;&#x06cbb;&#x07597;&#x07684;&#x08010;&#x0591a;&#x0836f;&#x07ed3;&#x06838;&#x075c5;&#x060a3;&#x08005;&#x07684;&#x06cbb;&#x07597;&#x06210;&#x0529f;&#x07387;&#x066f4;&#x09ad8;&#x03002; &#x09700;&#x08981;&#x05f00;&#x05c55;&#x08fdb;&#x04e00;&#x06b65;&#x07814;&#x07a76;&#x0ff0c;&#x04ee5;&#x063a2;&#x07d22;&#x08010;&#x0591a;&#x0836f;&#x07ed3;&#x06838;&#x075c5;&#x05206;&#x06563;&#x05316;&#x06cbb;&#x07597;&#x05728;&#x0591a;&#x079cd;&#x04e0d;&#x0540c;&#x073af;&#x05883;&#x04e0b;&#x07684;&#x06548;&#x0679c;&#x03002;</p></sec></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435;</title><sec><title>&#x00426;&#x00435;&#x0043b;&#x0044c;</title><p>&#x0041f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00441;&#x00442;&#x00438; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00443; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00434;&#x00435;&#x00446;&#x00435;&#x0043d;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x00444;&#x0043e;&#x00440;&#x0043c;&#x0044b; &#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x0043c;&#x00435;&#x00434;&#x00438;&#x00446;&#x00438;&#x0043d;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00449;&#x00438; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x00430;&#x0043c; &#x00441; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c; &#x00441;&#x0043e; &#x0043c;&#x0043d;&#x0043e;&#x00436;&#x00435;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x0043b;&#x00435;&#x0043a;&#x00430;&#x00440;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x00443;&#x00441;&#x00442;&#x0043e;&#x00439;&#x00447;&#x00438;&#x00432;&#x0043e;&#x00441;&#x00442;&#x0044c;&#x0044e;&#x000a0;(&#x0041c;&#x0041b;&#x00423;) &#x0043f;&#x0043e; &#x00441;&#x00440;&#x00430;&#x00432;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044e; &#x00441; &#x00446;&#x00435;&#x0043d;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x0043c;&#x00438; &#x0043f;&#x0043e;&#x00434;&#x00445;&#x0043e;&#x00434;&#x00430;&#x0043c;&#x00438;.</p></sec><sec><title>&#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;</title><p>&#x0041c;&#x0044b; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x0043b;&#x00438; &#x0043f;&#x0043e;&#x00438;&#x00441;&#x0043a; &#x00432; ClinicalTrials.gov, &#x0041a;&#x0043e;&#x0043a;&#x00440;&#x00430;&#x0043d;&#x0043e;&#x00432;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x00431;&#x00438;&#x00431;&#x0043b;&#x00438;&#x0043e;&#x00442;&#x00435;&#x0043a;&#x00435;, Embase&#x000ae;, Google Scholar, LILACS, PubMed&#x000ae;, Web of Science &#x00438; &#x0043d;&#x00430; &#x0043f;&#x0043e;&#x00440;&#x00442;&#x00430;&#x0043b;&#x00435; &#x0043a;&#x0043b;&#x00438;&#x0043d;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00445; &#x00438;&#x00441;&#x0043f;&#x0044b;&#x00442;&#x00430;&#x0043d;&#x00438;&#x00439; &#x00412;&#x00441;&#x00435;&#x0043c;&#x00438;&#x00440;&#x0043d;&#x0043e;&#x00439; &#x0043e;&#x00440;&#x00433;&#x00430;&#x0043d;&#x00438;&#x00437;&#x00430;&#x00446;&#x00438;&#x00438; &#x00437;&#x00434;&#x00440;&#x00430;&#x00432;&#x0043e;&#x0043e;&#x00445;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043d;&#x00430; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043c;&#x00435;&#x00442; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439;, &#x00432; &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00445; &#x00441;&#x0043e;&#x0043e;&#x00431;&#x00449;&#x00430;&#x00435;&#x00442;&#x00441;&#x0044f; &#x0043e; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x00430;&#x00445; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x00430; &#x00441; &#x0041c;&#x0041b;&#x00423; &#x0043f;&#x00440;&#x00438; &#x00434;&#x00435;&#x00446;&#x00435;&#x0043d;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x00438; &#x00446;&#x00435;&#x0043d;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x00444;&#x0043e;&#x00440;&#x0043c;&#x00435; &#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x0043c;&#x00435;&#x00434;&#x00438;&#x00446;&#x00438;&#x0043d;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00449;&#x00438;. &#x0041e;&#x00441;&#x0043d;&#x0043e;&#x00432;&#x0043d;&#x0044b;&#x0043c; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0043e;&#x0043c; &#x00431;&#x0044b;&#x0043b;&#x00430; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f;. &#x0041f;&#x0043e; &#x00432;&#x0043e;&#x00437;&#x0043c;&#x0043e;&#x00436;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043c;&#x0044b; &#x00442;&#x00430;&#x0043a;&#x00436;&#x00435; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x0043e;&#x00434;&#x00438;&#x0043b;&#x00438; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00443; &#x0043b;&#x00435;&#x00442;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;, &#x0043f;&#x0043e;&#x0043f;&#x00443;&#x0043b;&#x0044f;&#x00446;&#x00438;&#x00438; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432;, &#x00432;&#x0044b;&#x00431;&#x0044b;&#x00432;&#x00448;&#x00438;&#x00445; &#x00438;&#x00437; &#x0043f;&#x0043e;&#x00441;&#x0043b;&#x00435;&#x00434;&#x00443;&#x0044e;&#x00449;&#x00435;&#x00433;&#x0043e; &#x0043d;&#x00430;&#x00431;&#x0043b;&#x0044e;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f;, &#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043f;&#x00438;&#x00441;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x0043c;&#x00443; &#x00440;&#x00435;&#x00436;&#x00438;&#x0043c;&#x00443; &#x00438; &#x00437;&#x00430;&#x00442;&#x00440;&#x00430;&#x00442; &#x00432; &#x00441;&#x00438;&#x00441;&#x00442;&#x00435;&#x0043c;&#x00435; &#x00437;&#x00434;&#x00440;&#x00430;&#x00432;&#x0043e;&#x0043e;&#x00445;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f;. &#x00427;&#x00442;&#x0043e;&#x00431;&#x0044b; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00438;&#x00442;&#x0044c; &#x0043e;&#x00431;&#x0044a;&#x00435;&#x00434;&#x00438;&#x0043d;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00438; &#x0043e;&#x00442;&#x0043d;&#x0043e;&#x00448;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00440;&#x00438;&#x00441;&#x0043a;&#x0043e;&#x00432;&#x000a0;(&#x0041e;&#x00420;), &#x0043c;&#x0044b; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x0043b;&#x00438; &#x0043c;&#x00435;&#x00442;&#x00430;&#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x0044b; &#x00441; &#x00438;&#x00441;&#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x0043c;&#x0043e;&#x00434;&#x00435;&#x0043b;&#x00438; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00439;&#x0043d;&#x0044b;&#x00445; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x0043e;&#x00432;.</p></sec><sec><title>&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;</title><p>&#x00412;&#x0043e;&#x00441;&#x00435;&#x0043c;&#x0044c; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439; &#x00441;&#x0043e;&#x0043e;&#x00442;&#x00432;&#x00435;&#x00442;&#x00441;&#x00442;&#x00432;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00438; &#x0043a;&#x00440;&#x00438;&#x00442;&#x00435;&#x00440;&#x00438;&#x0044f;&#x0043c; &#x0043f;&#x00440;&#x00438;&#x00435;&#x0043c;&#x0043b;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00434;&#x0043b;&#x0044f; &#x00432;&#x0043a;&#x0043b;&#x0044e;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00432; &#x0043e;&#x00431;&#x00437;&#x0043e;&#x00440;. &#x00412; &#x00448;&#x00435;&#x00441;&#x00442;&#x00438; &#x0043a;&#x0043e;&#x00433;&#x0043e;&#x00440;&#x00442;&#x0043d;&#x0044b;&#x00445; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;&#x00445;, &#x00432; &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00445; &#x00443;&#x00447;&#x00430;&#x00441;&#x00442;&#x00432;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x0043e; 4026&#x000a0;&#x00447;&#x00435;&#x0043b;&#x0043e;&#x00432;&#x00435;&#x0043a;, &#x00441;&#x0043e;&#x0043e;&#x00431;&#x00449;&#x00430;&#x0043b;&#x0043e;&#x00441;&#x0044c; &#x0043e; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x00430;&#x00445; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f;. &#x0041e;&#x00431;&#x0044a;&#x00435;&#x00434;&#x00438;&#x0043d;&#x00435;&#x0043d;&#x0043d;&#x00430;&#x0044f; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00430; &#x0041e;&#x00420; &#x00434;&#x0043b;&#x0044f; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x00440;&#x00438; &#x00434;&#x00435;&#x00446;&#x00435;&#x0043d;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x00438; &#x00446;&#x00435;&#x0043d;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x00444;&#x0043e;&#x00440;&#x0043c;&#x00430;&#x00445; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00441;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x00438;&#x0043b;&#x00430; 1,13&#x000a0;(95%-&#x00439; &#x00414;&#x00418;: 1,01&#x02013;1,27). &#x00421;&#x0043e;&#x0043e;&#x00442;&#x00432;&#x00435;&#x00442;&#x00441;&#x00442;&#x00432;&#x00443;&#x0044e;&#x00449;&#x00438;&#x0043c;&#x00438; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00430;&#x0043c;&#x00438; &#x0041e;&#x00420; &#x00434;&#x0043b;&#x0044f; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432;, &#x00432;&#x0044b;&#x00431;&#x0044b;&#x00432;&#x00448;&#x00438;&#x00445; &#x00438;&#x00437; &#x0043f;&#x0043e;&#x00441;&#x0043b;&#x00435;&#x00434;&#x00443;&#x0044e;&#x00449;&#x00435;&#x00433;&#x0043e; &#x0043d;&#x00430;&#x00431;&#x0043b;&#x0044e;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f;, &#x00431;&#x0044b;&#x0043b;&#x00438;: 0,66 (95%-&#x00439; &#x00414;&#x00418;: 0,38&#x02013;1,13), &#x0041e;&#x00420; &#x00434;&#x0043b;&#x0044f; &#x0043b;&#x00435;&#x00442;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;: 1,01 (95%-&#x00439; &#x00414;&#x00418;: 0,67&#x02013;1,52), &#x0041e;&#x00420; &#x00434;&#x0043b;&#x0044f; &#x00431;&#x00435;&#x00437;&#x00443;&#x00441;&#x0043f;&#x00435;&#x00448;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f;: 1,07 (95%-&#x00439; &#x00414;&#x00418;: 0,48&#x02013;2,40). &#x00412; &#x00434;&#x00432;&#x00443;&#x00445; &#x00438;&#x00437; &#x00442;&#x00440;&#x00435;&#x00445; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439;, &#x00432; &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00445; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x0043e;&#x00434;&#x00438;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00430; &#x00437;&#x00430;&#x00442;&#x00440;&#x00430;&#x00442; &#x00432; &#x00441;&#x00438;&#x00441;&#x00442;&#x00435;&#x0043c;&#x00435; &#x00437;&#x00434;&#x00440;&#x00430;&#x00432;&#x0043e;&#x0043e;&#x00445;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f;, &#x00441;&#x0043e;&#x0043e;&#x00431;&#x00449;&#x00430;&#x0043b;&#x0043e;&#x00441;&#x0044c; &#x0043e; &#x00431;&#x0043e;&#x0043b;&#x00435;&#x00435; &#x0043d;&#x00438;&#x00437;&#x0043a;&#x00438;&#x00445; &#x00437;&#x00430;&#x00442;&#x00440;&#x00430;&#x00442;&#x00430;&#x00445; &#x0043f;&#x00440;&#x00438; &#x00434;&#x00435;&#x00446;&#x00435;&#x0043d;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x00444;&#x0043e;&#x00440;&#x0043c;&#x00435; &#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x0043c;&#x00435;&#x00434;&#x00438;&#x00446;&#x00438;&#x0043d;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00449;&#x00438; &#x0043f;&#x0043e; &#x00441;&#x00440;&#x00430;&#x00432;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044e; &#x00441; &#x00446;&#x00435;&#x0043d;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x0043c;&#x0043e;&#x00434;&#x00435;&#x0043b;&#x0044c;&#x0044e;.</p></sec><sec><title>&#x00412;&#x0044b;&#x00432;&#x0043e;&#x00434;</title><p>&#x0042d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00431;&#x0044b;&#x0043b;&#x00430; &#x00431;&#x0043e;&#x0043b;&#x00435;&#x00435; &#x00432;&#x00435;&#x00440;&#x0043e;&#x0044f;&#x00442;&#x0043d;&#x0043e;&#x00439; &#x00441;&#x00440;&#x00435;&#x00434;&#x00438; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432; &#x00441; &#x0041c;&#x0041b;&#x00423;-&#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c;, &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00432;&#x00448;&#x00438;&#x00445; &#x0043c;&#x00435;&#x00434;&#x00438;&#x00446;&#x00438;&#x0043d;&#x00441;&#x0043a;&#x00443;&#x0044e; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00449;&#x0044c; &#x00441; &#x00438;&#x00441;&#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x00434;&#x00435;&#x00446;&#x00435;&#x0043d;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043f;&#x0043e;&#x00434;&#x00445;&#x0043e;&#x00434;&#x00430;. &#x0041d;&#x00435;&#x0043e;&#x00431;&#x00445;&#x0043e;&#x00434;&#x00438;&#x0043c;&#x0044b; &#x00434;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x00435;&#x00439;&#x00448;&#x00438;&#x00435; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00434;&#x0043b;&#x0044f; &#x00438;&#x00437;&#x00443;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00434;&#x00435;&#x00446;&#x00435;&#x0043d;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043f;&#x0043e;&#x00434;&#x00445;&#x0043e;&#x00434;&#x00430; &#x0043f;&#x00440;&#x00438; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x00430; &#x00441; &#x0041c;&#x0041b;&#x00423; &#x00432; &#x00440;&#x00430;&#x00437;&#x0043b;&#x00438;&#x00447;&#x0043d;&#x0044b;&#x00445; &#x00443;&#x00441;&#x0043b;&#x0043e;&#x00432;&#x00438;&#x0044f;&#x00445;.<bold/></p></sec></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p><italic>Mycobacterium tuberculosis</italic> resistant to both isoniazid and rifampicin, so-called multidrug resistance, poses a major threat to the control of tuberculosis worldwide. In 2015, there were an estimated 480&#x02009;000 new cases of multidrug-resistant (MDR) tuberculosis, an additional 100&#x02009;000 cases with rifampicin resistance that also required treatment with second-line medicines, and approximately 250&#x02009;000 deaths from MDR tuberculosis.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> An estimated 9.5% of people with MDR tuberculosis have extensively drug-resistant (XDR) tuberculosis &#x02013; i.e. MDR tuberculosis that is also resistant to a second-line injectable drug and a fluoroquinolone. It has been estimated that, of all the cases of MDR tuberculosis that commenced treatment in 2013, only 52% achieved treatment success and the rest died (17%), were lost to follow-up or otherwise not evaluated (22%) or were identified as treatment failures (9%).<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> The recommended therapy for MDR tuberculosis requires a combination of second-line drugs that are, in general, more costly, less efficacious, more toxic and must be taken for much longer than the first-line drugs used against tuberculosis.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref></p><p>Historically, treatment for MDR tuberculosis has been provided through specialized, centralized programmes and typically involved prolonged inpatient care.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> This approach is based on the view that treatment adherence, the management of adverse events and infection control may be better in hospital settings than in the community.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="R5" ref-type="bibr"><sup>5</sup></xref> However, in many centralized facilities, insufficient resources preclude the prolonged inpatient care of cases of MDR tuberculosis. Reliance on centralized treatment, especially in facilities that lack effective infection control and where treatment may be delayed until inpatient beds become available, may inadvertently increase the risk of transmission of MDR <italic>M. tuberculosis</italic>. In addition, in comparison with decentralized interventions, centralized approaches have been associated with poorer rates of retention in care.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> In the treatment of drug-susceptible tuberculosis, decentralized care is well established and appears as effective as hospital-based approaches.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref><sup>&#x02013;</sup><xref rid="R9" ref-type="bibr"><sup>9</sup></xref> Since 2011, the World Health Organization (WHO) has recommended that &#x0201c;patients with multidrug-resistant tuberculosis should be treated using mainly ambulatory care&#x0201d;.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> This recommendation was, however, based on the results of a small number of uncontrolled studies.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref></p><p>We recently performed a systematic review and meta-analysis to try to determine if &#x02013; compared with treatment and care provided solely by specialized centres for the treatment of MDR tuberculosis &#x02013; decentralized treatment and care for MDR tuberculosis patients was more or less likely to lead to improved treatment outcomes, treatment adherence, adverse events, acquired drug resistance, lower patient costs and lower health-system costs. Our results have already contributed to forthcoming, revised WHO guidelines for the treatment of tuberculosis.</p></sec><sec sec-type="methods"><title>Methods</title><p>Our systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref></p><sec><title>Study eligibility</title><p>Studies were eligible if they included both patients receiving decentralized care and patients receiving centralized care &#x02013; as defined below. Studies were excluded if they lacked a comparator group or enrolled fewer than 10 participants in the intervention arm. This approach enabled a direct comparison to be performed between individuals receiving either model of care in the same setting. Included studies needed to report on at least one clinical outcome &#x02013; i.e. treatment adherence, the standard WHO-defined tuberculosis treatment outcomes of cure, completion, death, failure or relapse<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> and/or adverse reactions. Studies reporting costs, to patients and/or health systems, were also included. We included case&#x02013;control studies that each included at least 10 patients, modelling studies, prospective cohorts, randomized controlled trials and retrospective cohorts. Unpublished studies were sought through consultation with experts in the field and by hand-searching the International Union of Tuberculosis and Lung Disease&#x02019;s database of conference abstracts,<xref rid="R12" ref-type="bibr"><sup>12</sup></xref> OpenSIGLE<xref rid="R13" ref-type="bibr"><sup>13</sup></xref> and other grey literature.</p><p>We considered patients with MDR tuberculosis to be those with a microbiological or clinical diagnosis of MDR tuberculosis &#x02013; including XDR tuberculosis &#x02013; that had commenced second-line drug therapy. A clinical diagnosis included contacts &#x02013; exposed to patients with MDR tuberculosis &#x02013; who developed signs and symptoms of tuberculosis but were not microbiologically confirmed as cases. Decentralized care was defined as treatment and care provided in the community where the patient resided &#x02013; e.g. in a community centre, a peripheral health centre or the patient&#x02019;s home or workplace. A key component of the definition of decentralized care was the use of non-specialized workers &#x02013; e.g. community workers, treatment supporters or volunteers.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> Even with care that we considered decentralized, an initial period of hospitalization during the initiation of therapy was permissible, so long as the majority of care was delivered in a decentralized fashion. To be considered centralized, care had to have been provided solely by specialist centres for the treatment of MDR tuberculosis, either in such a centre &#x02013; as an inpatient and/or outpatient &#x02013; or in outpatient facilities near to such a centre.</p><p>Our outcomes of interest included treatment adherence, the standard WHO-defined tuberculosis treatment outcomes of cure, completion, death and failure,<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> adverse reactions and patient and/or health-system costs.</p></sec><sec><title>Search strategy</title><p>We searched for relevant publications in ClinicalTrials.gov, the Cochrane library, Embase&#x000ae;, Google Scholar, LILACS, PubMed&#x000ae;, Web of Science and the World Health Organization&#x02019;s portal of clinical trials. We developed a sensitive search strategy to detect articles on MDR tuberculosis that mentioned community-based care and/or decentralized care. The search terms used with PubMed&#x000ae; are shown in <xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref>. Searches were limited to publications published between the start of 1995, i.e. the year in which the WHO-recommended directly observed treatment, short-course (DOTS) strategy was scaled-up, and 31 May 2016. The reference lists of all articles considered relevant were searched for reports of further eligible studies. Where the findings of a study were reported in brief in one paper and then more completely in a subsequent paper, only the latter was selected for inclusion in our review. If an abstract was the only report of a potentially eligible study that we could find, we attempted to contact the abstract&#x02019;s authors so that we could obtain additional information and ask the authors to complete a data-collection form. The authors of some other, fuller reports were also contacted to provide additional data, if required. Searches were not restricted by language. If eligible studies published in a language other than English were identified, these were translated by translators with experience in the field of tuberculosis.</p><boxed-text id="B1" position="float" orientation="portrait"><label>Box&#x000a0;1</label><caption><title>Search terms used with PubMed&#x000ae;</title></caption><sec><title>1. Tuberculosis, Multidrug-Resistant [MeSH]</title><p>OR</p><p>((tuberculosis OR TB) AND (multidrug-resistan* OR multidrug resistan* OR multi-drug resistan* OR &#x0201c;drug resistan*&#x0201d; OR drug-resistan* OR multiresistan* OR &#x0201c;multi resistan*&#x0201d; OR &#x0201c;rifampicin resistan*&#x0201d; OR &#x0201c;extensively drug-resistan*&#x0201d; OR &#x0201c;extensively-drug resistan*&#x0201d; OR &#x0201c;extensively resistan*&#x0201d; OR MDR OR XDR OR TDR))</p><p>OR</p><p>mdrtb OR xdr tb OR mdrtb OR mdr-tb OR xdr-tb OR tdr-tb OR &#x0201c;MDR TB&#x0201d; OR &#x0201c;XDR TB&#x0201d; OR &#x0201c;TDR TB&#x0201d;</p><p>AND</p></sec><sec><title>2. (&#x0201c;directly observed&#x0201d; OR DOT OR DOTS OR DOTS-Plus OR cb-DOTS OR treatment OR &#x0201c;patient support&#x0201d;)</title><p>AND</p><p>(community OR outpatient OR &#x0201c;public participation&#x0201d; OR community-based OR decentralized OR non-specialized OR &#x0201c;periph* health centres&#x0201d; OR home-based OR ambulatory OR clinic OR &#x0201c;community health worker&#x0201d; OR CHW OR volunteer)</p></sec></boxed-text></sec><sec><title>Data selection and extraction</title><p>Two reviewers independently screened all titles, abstracts and full-text articles, to identify the studies eligible for review inclusion, before two reviewers independently extracted data from all of the eligible reports. Differences between reviewers were resolved by consensus. We extracted the proportions of MDR tuberculosis patients from each study that were considered to be treatment successes, lost to follow-up, deaths or treatment failures. Other study characteristics recorded, when available, were adverse events, details about the decentralized and/or centralized care interventions, drug regimens used, health-system and patient costs, human immunodeficiency virus (HIV) prevalence, sample size and study design. We categorized the timing of the intervention, in relation to the control arm, as either concurrent or consecutive. Study quality was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref></p></sec><sec><title>Data analysis</title><p>We used forest plots, created using RevMan version 5.2 (The Nordic Cochrane Centre, Copenhagen), to summarize the data for individual trials. Outcomes were estimated, as pooled proportions, using the exact binomial method<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> and the statistical software SAS version 9.3 (SAS Institute, Cary, United States of America). We performed random-effects meta-analyses to account for between-study variability. Whenever the relevant data for an outcome of interest were available from three or more studies, we calculated the corresponding relative risk (RR) and 95% confidence interval (CI), for decentralized versus centralized care, using RevMan version 5.2 and a generalized linear mixed model, with study as a random effect. Heterogeneity between studies was evaluated as the <italic>I</italic><sup>2</sup> statistic.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="R17" ref-type="bibr"><sup>17</sup></xref> We planned to assess publication bias, using a funnel plot, if sufficient studies, i.e. at least five with the same end-point, were identified.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> We performed additional sensitivity analyses to explore the effect of removing the data from a study in which allocation to inpatient care had been highly selective and based on disease severity.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Seven published studies<xref rid="R19" ref-type="bibr"><sup>19</sup></xref><sup>&#x02013;</sup><xref rid="R25" ref-type="bibr"><sup>25</sup></xref> and one study considered to be unpublished met the eligibility criteria for inclusion (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>; <xref ref-type="table" rid="T1">Table&#x000a0;1</xref>). The data for the unpublished study, which took place in Swaziland in 2016, were kindly provided by B Kerschberger (M&#x000e9;decins Sans Fronti&#x000e8;res, Mbabane, Swaziland), the corresponding author of a conference abstract<xref rid="R26" ref-type="bibr"><sup>26</sup></xref> in which the study&#x02019;s initial findings were briefly summarized. Most of the excluded studies did not include a comparison group. We did not identify any relevant randomized controlled trials. Six cohort studies, with a combined total of 4026 participants, reported on treatment outcomes. Four of these were from low- or middle-income countries &#x02013; i.e. the Philippines,<xref rid="R21" ref-type="bibr"><sup>21</sup></xref> South Africa<xref rid="R20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="R22" ref-type="bibr"><sup>22</sup></xref> and Swaziland (B Kerschberger, unpublished data), and two from middle- and high-income countries, China <xref rid="R19" ref-type="bibr"><sup>19</sup></xref> and the United States of America (USA).<xref rid="R24" ref-type="bibr"><sup>24</sup></xref> The other two included studies were modelling studies on health-care costs.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="R25" ref-type="bibr"><sup>25</sup></xref> Of the six studies that reported on treatment outcomes, five evaluated treatment success (B Kerschberger, unpublished data),<xref rid="R19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="R20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="R22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref> four evaluated loss to follow-up (B Kerschberger, unpublished data),<xref rid="R20" ref-type="bibr"><sup>20</sup></xref><sup>&#x02013;</sup><xref rid="R22" ref-type="bibr"><sup>22</sup></xref> four evaluated death (B Kerschberger, unpublished data),<xref rid="R20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="R22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref> and three evaluated treatment failure(B Kerschberger, unpublished data).<xref rid="R20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="R22" ref-type="bibr"><sup>22</sup></xref> Decentralized care in some studies was based on treatment provision in patients&#x02019; homes while in other studies it was provided via community-based clinics or, in one study,<xref rid="R22" ref-type="bibr"><sup>22</sup></xref> via a rural hospital. Centralized care was provided in specialized hospitals, except in the unpublished study from Swaziland, in which home-based directly observed therapy provided by trained community volunteers was compared with clinic-based centralized care provided by nurses. Most decentralized and centralized care was based on the DOTS strategy (<xref ref-type="table" rid="T1">Table&#x000a0;1</xref>). There was no randomization of patient selection for decentralized care. Instead, allocation of sites to the intervention or control groups was based upon patient characteristics that were considered likely to make centralized care more difficult or less successful, e.g. living far from the centralized facility.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="R22" ref-type="bibr"><sup>22</sup></xref> In four of the six cohort studies, the patients were chosen for decentralized treatment based on their residential location, their socioeconomic status and their risk factors for loss to follow-up (B Kerschberger, unpublished data).<xref rid="R20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="R22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref> In the other two cohort studies, treatment of the intervention and control groups occurred consecutively &#x02013; i.e. care was initially provided by a centralized system that was subsequently replaced with a programme of decentralized care.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="R21" ref-type="bibr"><sup>21</sup></xref> None of the studies reported on acquisition of drug resistance, patient costs or treatment adherence.</p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Flowchart showing the selection of studies on the centralized and decentralized care of patients with multidrug-resistant tuberculosis</p></caption><graphic xlink:href="BLT.17.193375-F1"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Key characteristics of the eight studies included in the systematic review of decentralized versus centralized care for multidrug-resistant tuberculosis, 1994&#x02013;2013</title></caption><table frame="hsides" rules="groups"><col width="85" span="1"/><col width="77" span="1"/><col width="49" span="1"/><col width="63" span="1"/><col width="77" span="1"/><col width="77" span="1"/><col width="92" span="1"/><col width="85" span="1"/><col width="70" span="1"/><col width="85" span="1"/><col width="106" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Author, year, location</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Study design</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Year of intervention</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Sample size for intervention/control</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">HIV prevalence in study population (%)</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Description of arms<hr/></th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Method of selection of intervention group</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Timing of intervention<hr/></th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Outcomes measured</th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Control</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Intervention</th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Within treatment</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Relative to control</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Loveday et al.<xref rid="R22" ref-type="bibr"><sup>22</sup></xref> 2015, KwaZulu-Natal, South Africa </td><td valign="top" align="left" rowspan="1" colspan="1">Prospective cohort</td><td valign="top" align="center" rowspan="1" colspan="1">2008&#x02013;2010</td><td valign="top" align="center" rowspan="1" colspan="1">736/813</td><td valign="top" align="center" rowspan="1" colspan="1">75</td><td valign="top" align="left" rowspan="1" colspan="1">Treatment in central specialized tuberculosis hospital</td><td valign="top" align="left" rowspan="1" colspan="1">Treatment in rural hospital followed by outpatient home- or clinic-based DOT, by health workers</td><td valign="top" align="left" rowspan="1" colspan="1">Based on residential location</td><td valign="top" align="left" rowspan="1" colspan="1">Intensive phase<sup>a</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Concurrent</td><td valign="top" align="left" rowspan="1" colspan="1">Death, loss to follow-up, treatment failure, treatment success</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chan et al.<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> 2013, Taiwan, China </td><td valign="top" align="left" rowspan="1" colspan="1">Retrospective cohort</td><td valign="top" align="center" rowspan="1" colspan="1">2007&#x02013;2008</td><td valign="top" align="center" rowspan="1" colspan="1">290/361</td><td valign="top" align="center" rowspan="1" colspan="1">0.9</td><td valign="top" align="left" rowspan="1" colspan="1">Hospital and out-patient clinics</td><td valign="top" align="left" rowspan="1" colspan="1">Home- based DOT, by observers and nurses</td><td valign="top" align="left" rowspan="1" colspan="1">Time period</td><td valign="top" align="left" rowspan="1" colspan="1">Entire duration of treatment</td><td valign="top" align="left" rowspan="1" colspan="1">Consecutive</td><td valign="top" align="left" rowspan="1" colspan="1">Treatment success</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kerschberger et al.<sup>b</sup> 2016, Swaziland</td><td valign="top" align="left" rowspan="1" colspan="1">Retrospective cohort</td><td valign="top" align="center" rowspan="1" colspan="1">2008&#x02013;2013</td><td valign="top" align="center" rowspan="1" colspan="1">157/298</td><td valign="top" align="center" rowspan="1" colspan="1">81</td><td valign="top" align="left" rowspan="1" colspan="1">Clinic-based care in which patients visited nearest health facility daily</td><td valign="top" align="left" rowspan="1" colspan="1">Home-based DOT, by trained community volunteers</td><td valign="top" align="left" rowspan="1" colspan="1">Based on residential location and socioeconomic status</td><td valign="top" align="left" rowspan="1" colspan="1">Intensive phase</td><td valign="top" align="left" rowspan="1" colspan="1">Concurrent</td><td valign="top" align="left" rowspan="1" colspan="1">Cost of care, death, loss to follow-up, treatment failure, treatment success</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Narita et al.<xref rid="R24" ref-type="bibr"><sup>24</sup></xref> 2001, Florida, USA </td><td valign="top" align="left" rowspan="1" colspan="1">Retrospective cohort </td><td valign="top" align="center" rowspan="1" colspan="1">1994&#x02013;1997</td><td valign="top" align="center" rowspan="1" colspan="1">31/39</td><td valign="top" align="center" rowspan="1" colspan="1">44.3</td><td valign="top" align="left" rowspan="1" colspan="1">Treatment in specialized tuberculosis hospital</td><td valign="top" align="left" rowspan="1" colspan="1">Outpatient DOT and/or SAT</td><td valign="top" align="left" rowspan="1" colspan="1">Selected for control if: failing treatment, needed treatment of other medical condition and/or non-adherent</td><td valign="top" align="left" rowspan="1" colspan="1">Entire duration of treatment</td><td valign="top" align="left" rowspan="1" colspan="1">Concurrent</td><td valign="top" align="left" rowspan="1" colspan="1">Death, treatment completion</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gler et al.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref> 2012, Philippines</td><td valign="top" align="left" rowspan="1" colspan="1">Retrospective cohort </td><td valign="top" align="center" rowspan="1" colspan="1">2003&#x02013;2006</td><td valign="top" align="center" rowspan="1" colspan="1">167/416</td><td valign="top" align="center" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">Treatment in central hospital</td><td valign="top" align="left" rowspan="1" colspan="1">Community- based DOT, by trained health-care workers</td><td valign="top" align="left" rowspan="1" colspan="1">Time period</td><td valign="top" align="left" rowspan="1" colspan="1">After sputum-culture conversion</td><td valign="top" align="left" rowspan="1" colspan="1">Consecutive</td><td valign="top" align="left" rowspan="1" colspan="1">Loss to follow-up</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cox et al.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> 2014, Khayelitsha, South Africa </td><td valign="top" align="left" rowspan="1" colspan="1">Retrospective cohort </td><td valign="top" align="center" rowspan="1" colspan="1">2008&#x02013;2010</td><td valign="top" align="center" rowspan="1" colspan="1">512/206</td><td valign="top" align="center" rowspan="1" colspan="1">72</td><td valign="top" align="left" rowspan="1" colspan="1">Hospital-based care</td><td valign="top" align="left" rowspan="1" colspan="1">Community-based care integrated into existing primary care tuberculosis and HIV services.</td><td valign="top" align="left" rowspan="1" colspan="1">Based on residential location</td><td valign="top" align="left" rowspan="1" colspan="1">Entire duration of treatment</td><td valign="top" align="left" rowspan="1" colspan="1">Consecutive</td><td valign="top" align="left" rowspan="1" colspan="1">Death, loss to follow-up, treatment failure, treatment success</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Musa et al.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref> 2016, Nigeria</td><td valign="top" align="left" rowspan="1" colspan="1">Modelling </td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">Hospital-based care</td><td valign="top" align="left" rowspan="1" colspan="1">Home-based DOT, by trained health-care providers</td><td valign="top" align="left" rowspan="1" colspan="1">Random selection</td><td valign="top" align="left" rowspan="1" colspan="1">Intensive phase</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Health-system costs</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sinanovic et al.<xref rid="R25" ref-type="bibr"><sup>25</sup></xref> 2015, Khayelitsha, South Africa</td><td valign="top" align="left" rowspan="1" colspan="1">Modelling </td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">467<sup>c</sup></td><td valign="top" align="center" rowspan="1" colspan="1">72</td><td valign="top" align="left" rowspan="1" colspan="1">Fully hospitalized model in which patients stay in hospital until culture conversion</td><td valign="top" align="left" rowspan="1" colspan="1">A model of fully decentralized care in primary health-care clinics, plus other models of partially decentralized care</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Entire duration of treatment</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Health-system costs</td></tr></tbody></table><table-wrap-foot><p>DOT:&#x02009;directly observed therapy; HIV: human immunodeficiency virus; N/A:&#x02009;not applicable; NR: not reported; SAT: self-administered therapy; USA: United States of America.</p><p><sup>a</sup> Intensive phase defined by inclusion of an injectable antibiotic in the treatment regimen.</p><p><sup>b</sup> Unpublished study from M&#x000e9;decins Sans Fronti&#x000e8;res, Mbabane, Swaziland, 2016.</p><p><sup>c</sup> Total number of patients used in four different models of multidrug-resistant tuberculosis care.</p></table-wrap-foot></table-wrap><p>The pooled proportions of each treatment outcome are shown, separately for decentralized and centralized care, in <xref ref-type="table" rid="T2">Table&#x000a0;2</xref>. Overall, treatment success was achieved in 67.3% (95% CI: 53.8&#x02013;78.5%) of patients who received decentralized care compared with 61.0% (95% CI: 49.0&#x02013;71.7%) of those treated with centralized care. <xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref>, <xref ref-type="fig" rid="F3">Fig.&#x000a0;3</xref>, <xref ref-type="fig" rid="F4">Fig.&#x000a0;4</xref> and <xref ref-type="fig" rid="F5">Fig.&#x000a0;5</xref> are forest plots showing the RRs for the various treatment outcomes. Treatment success was significantly more common among those receiving decentralized care than among those in the centralized care group (RR:&#x02009;1.13; 95% CI: 1.01&#x02013;1.27; <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;74%). Although loss to follow-up was relatively less common with decentralized care than with centralized, the difference was not statistically significant (RR:&#x02009;0.66; 95% CI: 0.38&#x02013;1.13; <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;88%). The proportions of death (RR:&#x02009;1.01; 95% CI: 0.67&#x02013;1.52; <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;77%) and treatment failure (RR:&#x02009;1.07; 95% CI: 0.48&#x02013;2.40; <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;74%) with decentralized care were similar to those observed with centralized care. Owing to the small number of eligible studies, we could not assess publication bias formally.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Proportions of patients with multidrug-resistant tuberculosis who achieved treatment success after receiving decentralized and centralized care, five countries, 1994&#x02013;2013</title></caption><table frame="hsides" rules="groups"><col width="97" span="1"/><col width="63" span="1"/><col width="71" span="1"/><col width="59" span="1"/><col width="53" span="1"/><col width="69" span="1"/><col width="11" span="1"/><col width="60" span="1"/><col width="70" span="1"/><col width="48" span="1"/><col width="59" span="1"/><col width="70" span="1"/><thead><tr><th rowspan="3" valign="top" align="left" scope="col" colspan="1">Study</th><th colspan="5" valign="top" align="center" scope="colgroup" rowspan="1">Centralized care<hr/></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"/><th colspan="5" valign="top" align="center" scope="colgroup" rowspan="1">Decentralized care<hr/></th></tr><tr><th rowspan="2" valign="top" colspan="1" align="center" scope="colgroup">Total patients</th><th colspan="4" valign="top" align="center" scope="colgroup" rowspan="1">No. of patients (%)<hr/></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"/><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Total patients</th><th colspan="4" valign="top" align="center" scope="colgroup" rowspan="1">No. of patients (%)<hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Treatment success<bold><sup>a</sup></bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Loss to follow-up</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Death</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Treatment failure</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"/><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Treatment success <bold><sup>a</sup></bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Loss to follow-up</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Death</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Treatment failure</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chan et al.<xref rid="R19" ref-type="bibr"><sup>19</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">361</td><td valign="top" align="center" rowspan="1" colspan="1">222 (61.5)</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">290</td><td valign="top" align="center" rowspan="1" colspan="1">239 (82.4)</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cox et al.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">206</td><td valign="top" align="center" rowspan="1" colspan="1">85 (41.3)</td><td valign="top" align="center" rowspan="1" colspan="1">59 (28.6)</td><td valign="top" align="center" rowspan="1" colspan="1">43 (20.9)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (9.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">512</td><td valign="top" align="center" rowspan="1" colspan="1">235 (45.9)</td><td valign="top" align="center" rowspan="1" colspan="1">152 (29.7)</td><td valign="top" align="center" rowspan="1" colspan="1">85 (16.6)</td><td valign="top" align="center" rowspan="1" colspan="1">40 (7.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kerschberger et al.<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">294</td><td valign="top" align="center" rowspan="1" colspan="1">202 (68.7)</td><td valign="top" align="center" rowspan="1" colspan="1">16 (5.4)</td><td valign="top" align="center" rowspan="1" colspan="1">69 (23.5)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">154</td><td valign="top" align="center" rowspan="1" colspan="1">119 (77.3)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (6.5)</td><td valign="top" align="center" rowspan="1" colspan="1">24 (15.6)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Loveday et al.<xref rid="R22" ref-type="bibr"><sup>22</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">811</td><td valign="top" align="center" rowspan="1" colspan="1">439 (54.1)</td><td valign="top" align="center" rowspan="1" colspan="1">230 (28.4)</td><td valign="top" align="center" rowspan="1" colspan="1">113 (13.9)</td><td valign="top" align="center" rowspan="1" colspan="1">29 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">716</td><td valign="top" align="center" rowspan="1" colspan="1">427 (59.6)</td><td valign="top" align="center" rowspan="1" colspan="1">107 (14.9)</td><td valign="top" align="center" rowspan="1" colspan="1">133 (18.6)</td><td valign="top" align="center" rowspan="1" colspan="1">49 (6.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Narita et al.<xref rid="R24" ref-type="bibr"><sup>24</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">38</td><td valign="top" align="center" rowspan="1" colspan="1">31 (81.6)</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td><td valign="top" align="center" rowspan="1" colspan="1">7 (18.4)</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">23</td><td valign="top" align="center" rowspan="1" colspan="1">15 (65.2)</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td><td valign="top" align="center" rowspan="1" colspan="1">8 (34.8)</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gler et al.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">416</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td><td valign="top" align="center" rowspan="1" colspan="1">79 (19.0)</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">167</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td><td valign="top" align="center" rowspan="1" colspan="1">9 (5.4)</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td><td valign="top" align="center" rowspan="1" colspan="1">ONA</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>All six studies</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Outcome/ total no. of patients (pooled percentage; 95% CI)</td><td valign="top" align="center" rowspan="1" colspan="1">2126</td><td valign="top" align="center" rowspan="1" colspan="1">979/1710 (61.0; 49.0&#x02013;71.7)</td><td valign="top" align="center" rowspan="1" colspan="1">384/1727 (18.0; 9.3&#x02013;31.8)</td><td valign="top" align="center" rowspan="1" colspan="1">232/1349 (18.6; 14.5&#x02013;23.6)</td><td valign="top" align="center" rowspan="1" colspan="1">55/1311 (4.3; 2.3&#x02013;8.1)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1862</td><td valign="top" align="center" rowspan="1" colspan="1">1035/1695 (67.3; 53.8&#x02013;78.5)</td><td valign="top" align="center" rowspan="1" colspan="1">278/1549 (11.9; 5.7&#x02013;23.3)</td><td valign="top" align="center" rowspan="1" colspan="1">250/1405 (17.8; 15.9&#x02013;19.9)</td><td valign="top" align="center" rowspan="1" colspan="1">90/1382 (4.2; 1.4&#x02013;11.9)</td></tr></tbody></table><table-wrap-foot><p>CI: confidence interval; ONA: outcome not assessed.</p><p><sup>a</sup> Includes treatment completion and cure.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref></p><p><sup>b</sup> Unpublished study from M&#x000e9;decins Sans Fronti&#x000e8;res, Mbabane, Swaziland, 2016.</p></table-wrap-foot></table-wrap><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Relative risks for treatment success following the decentralized care of multidrug-resistant tuberculosis &#x02013; compared with centralized care, 1994&#x02013;2013</p></caption><p>CI: confidence interval; df: degrees of freedom; RR: relative risk.</p><p>Notes: This forest plot summarizes the main results of a random-effects meta-analysis of the data from five studies. To be considered a treatment success, a patient had to show no evidence of failure after completing treatment recommended by national policy.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref></p><graphic xlink:href="BLT.17.193375-F2"/></fig><fig id="F3" fig-type="figure" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Relative risks for loss to follow-up during the decentralized care of multidrug-resistant tuberculosis &#x02013; compared with centralized care, 2003&#x02013;2013</p></caption><p>CI: confidence interval; df: degrees of freedom; RR: relative risk.</p><p>Notes: This forest plot summarizes the main results of a random-effects meta-analysis of the data from four studies. A patient whose treatment was interrupted for at least two consecutive months was considered lost to follow-up.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref></p><graphic xlink:href="BLT.17.193375-F3"/></fig><fig id="F4" fig-type="figure" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Relative risks for death during the decentralized care of multidrug-resistant tuberculosis &#x02013; compared with centralized care, 1994&#x02013;2013</p></caption><p>CI: confidence interval; df: degrees of freedom; RR: relative risk.</p><p>Notes: This forest plot summarizes the main results of a random-effects meta-analysis of the data from four studies. Death was the treatment outcome recorded for any patients who died, for any reason, during the course of treatment.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref></p><graphic xlink:href="BLT.17.193375-F4"/></fig><fig id="F5" fig-type="figure" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Relative risks for treatment failure following the decentralized care of multidrug-resistant tuberculosis &#x02013; compared with centralized care, 2008&#x02013;2013</p></caption><p>CI: confidence interval; df: degrees of freedom; RR: relative risk.</p><p>Notes: This forest plot summarizes the main results of a random-effects meta-analysis of the data from three studies. Treatment failure&#x02009;was the outcome recorded when &#x02013; because of a lack of conversion by the end of the intensive phase, bacteriological reversion in the continuation phase after conversion to negative, evidence of additional acquired resistance to fluoroquinolones or second-line injectable drugs or adverse drug reactions &#x02013; treatment was terminated or there was a need for a permanent regimen change involving at least two anti-tuberculosis drugs.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref></p><graphic xlink:href="BLT.17.193375-F5"/></fig><p>In terms of the method of assigning patients to the intervention and control groups, one study differed markedly from the other included studies. In this one study,<xref rid="R24" ref-type="bibr"><sup>24</sup></xref> only patients who were failing treatment or non-adherent were selected for care in a specialized tuberculosis hospital. However, when, in a sensitivity analysis, we excluded data from this one study, our estimates of RRs remained largely unchanged.</p><p>Three studies, i.e. both modelling studies<xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="R25" ref-type="bibr"><sup>25</sup></xref> and the unpublished cohort study, reported on the health-system costs associated with decentralized and centralized care (<xref ref-type="table" rid="T3">Table&#x000a0;3</xref>). In both the modelling studies, from Nigeria<xref rid="R23" ref-type="bibr"><sup>23</sup></xref> and South Africa,<xref rid="R25" ref-type="bibr"><sup>25</sup></xref> decentralized care appeared to offer substantial cost savings compared with centralized care. In the retrospective cohort study from Swaziland (B Kerschberger, unpublished data), however, the estimated treatment costs with centralized care appeared very similar to those with decentralized care.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Estimated health-system costs for treatment of patients with multidrug-resistant tuberculosis receiving decentralized and centralized care</title></caption><table frame="hsides" rules="groups"><col width="59" span="1"/><col width="60" span="1"/><col width="47" span="1"/><col width="55" span="1"/><col width="60" span="1"/><col width="11" span="1"/><col width="55" span="1"/><col width="60" span="1"/><col width="52" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Study</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Study design</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Country</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Decentralized care<hr/></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"/><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Centralized care<hr/></th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Difference in per-patient costs of centralized care<bold><sup>a</sup></bold></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Description</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Cost (US$/patient)</th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Description</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Cost (US$/patient)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Musa et al.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Modelling of costs from a health-systems perspective</td><td valign="top" align="left" rowspan="1" colspan="1">Nigeria</td><td valign="top" align="left" rowspan="1" colspan="1">Home-based care for entire duration of treatment</td><td valign="top" align="center" rowspan="1" colspan="1">1535</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Hospital-based care for intensive phase, then home-based care for continuation phase</td><td valign="top" align="left" rowspan="1" colspan="1">2095</td><td valign="top" align="left" rowspan="1" colspan="1">37% higher</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sinanovic et al.<xref rid="R25" ref-type="bibr"><sup>25</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Modelling of costs from a health-systems perspective</td><td valign="top" align="left" rowspan="1" colspan="1">South Africa</td><td valign="top" align="left" rowspan="1" colspan="1">Primary health-care clinic for entire duration of treatment</td><td valign="top" align="center" rowspan="1" colspan="1">7753<sup>b</sup></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Hospital-based care for intensive phase &#x02013; until 4-month culture conversion &#x02013; then clinic-based care</td><td valign="top" align="left" rowspan="1" colspan="1">13&#x02009;432<sup>c</sup></td><td valign="top" align="left" rowspan="1" colspan="1">42% higher</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kerschberger et al.<sup>d</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Retrospective cohort study</td><td valign="top" align="left" rowspan="1" colspan="1">Swaziland</td><td valign="top" align="left" rowspan="1" colspan="1">Home-based care for entire duration of treatment</td><td valign="top" align="center" rowspan="1" colspan="1">13&#x02009;361</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Clinic-based care for intensive phase, then home-based care for continuation phase</td><td valign="top" align="left" rowspan="1" colspan="1">13&#x02009;006</td><td valign="top" align="left" rowspan="1" colspan="1">3% lower</td></tr></tbody></table><table-wrap-foot><p>US$: United States dollars.</p><p><sup>a</sup> Compared with corresponding costs of decentralized care.</p><p><sup>b</sup> 95% confidence interval: 6917&#x02013;8522.</p><p><sup>c</sup> 95% confidence interval: 11&#x02009;165&#x02013;15&#x02009;494.</p><p><sup>d</sup> Unpublished study from M&#x000e9;decins Sans Fronti&#x000e8;res, Mbabane, Swaziland, 2016.</p></table-wrap-foot></table-wrap><p>According to the GRADE criteria,<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> the overall quality of the studies we used to estimate RRs was very low &#x02013; mainly because the studies were observational and considerable heterogeneity existed between them (available from corresponding author).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>In the treatment of patients with MDR tuberculosis, according to our meta-analysis, decentralized care appears to be more likely than centralized care to lead to treatment success. The loss to follow-up with decentralized care was lower &#x02013; although not significantly lower &#x02013; than with centralized care and the rates of death and treatment failure appeared unaffected by the type of care provided. Furthermore, from a health-system perspective, the decentralized approaches appeared either cost-neutral or cost-saving when compared with the centralized approaches.</p><p>There may be several explanations why, compared with centralized care, decentralized care was more likely to lead to treatment success. For example, although the small number of eligible studies limited the power of our meta-analysis, there is a hint that retention in care may be generally greater, or, at least, loss to follow-up may be generally rarer, when services are delivered locally. It seems likely that the delivery of care in the community could eliminate some of the barriers to treatment adherence that are encountered with often-more-distant centralized care. For example, the costs of hospitalization to patients and, often, their families may be prohibitive even if the tuberculosis treatment itself is provided free of charge.<xref rid="R27" ref-type="bibr"><sup>27</sup></xref> Local delivery of care may also facilitate greater support from patients&#x02019; families and their wider social networks, which may, in turn, increase the likelihood of adherence. We need further studies to examine the effect of decentralized MDR tuberculosis care on treatment adherence and patient attitudes to care.</p><p>All three studies on health-system costs that we included in our review were conducted in resource-poor low- or middle-income settings. Their conclusions &#x02013; that decentralized care was cheaper or as cheap as centralized care &#x02013; may not apply to high-income settings, where the costs of community-based care may be at least as high as those of centralized care. Further research is required to evaluate the impact of decentralized approaches on the costs to patients of treatment for MDR tuberculosis. The impact of such approaches on the elimination of catastrophic health expenditure for the households of such patients, which is one of the key targets of the WHO End TB Strategy,<xref rid="R28" ref-type="bibr"><sup>28</sup></xref> also needs to be investigated.</p><p>The strengths of our review include the comprehensive search of bibliographic databases and other information sources and our use of strict eligibility criteria to limit the review to studies in which cohorts receiving decentralized care were compared with those, from the same study population, receiving centralized care. The eligibility criteria we used, which reduced the risk of bias due to indirectness, were narrower than those used in previous systematic reviews on the care of patients with MDR tuberculosis.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="R30" ref-type="bibr"><sup>30</sup></xref></p><p>Our review also had several limitations. Substantial heterogeneity was observed between the included studies. This probably reflects the diversity in the study settings, patient populations and interventions involved. However, the effect estimates from every study in a tuberculosis-endemic setting that we included in our meta-analysis indicated that decentralized care was better &#x02013; at least in terms of the probability of treatment success &#x02013; than centralized care. The only study included from a low-prevalence country &#x02013; i.e. the United States &#x02013; indicated the opposite: that the probability of treatment success was lower with decentralized care than with centralized. Given the absence of randomized controlled trials, the frequent use of historical controls and the large level of heterogeneity between the studies, it is perhaps not surprising that we found that the overall quality of the studies we used to estimate RRs was categorized as low. This low quality places some limitations on the precision and generalizability of the results of our meta-analysis and underpins the importance of further research into the benefits of decentralized care for MDR tuberculosis in different settings. In countries where tuberculosis is endemic and national programmes increasingly adopt decentralized approaches for managing patients with MDR tuberculosis, the programmes&#x02019; interventions and outcomes need to be carefully and thoroughly reported. For future research in this field, before-and-after studies or pragmatic randomized studies &#x02013; e.g. stepped-wedge cluster randomized studies &#x02013; may be good choices. Well-designed operational research may enable programmes to evaluate the effectiveness of alternative approaches, in their local settings, accurately.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank Giuliano Gargioni and Dennis Falzon, from the WHO Global TB Programme.</p></ack><fn-group><title>Funding:</title><fn fn-type="supported-by"><p>The Australian National Health and Medical Research Council and the United States Agency for International Development supported this study.</p></fn></fn-group><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="book"><source>Global tuberculosis report 2015.</source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="book"><source>Guidelines for the programmatic management of drug-resistant tuberculosis &#x02013; 2011 update.</source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2011</year>.</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><string-name><surname>Nathanson</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Lambregts-van Weezenbeek</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Rich</surname>
<given-names>ML</given-names></string-name>, <string-name><surname>Gupta</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Bayona</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Bl&#x000f6;ndal</surname>
<given-names>K</given-names></string-name>, <etal>et al.</etal>
<article-title>Multidrug-resistant tuberculosis management in resource-limited settings.</article-title>
<source>Emerg Infect Dis</source>. <year>2006</year>
<month>9</month>;<volume>12</volume>(<issue>9</issue>):<fpage>1389</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.3201/eid1209.051618</pub-id><pub-id pub-id-type="pmid">17073088</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><string-name><surname>Burgos</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gonzalez</surname>
<given-names>LC</given-names></string-name>, <string-name><surname>Paz</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Gournis</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Kawamura</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Schecter</surname>
<given-names>G</given-names></string-name>, <etal>et al.</etal>
<article-title>Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach.</article-title>
<source>Clin Infect Dis</source>. <year>2005</year>
<month>4</month>
<day>1</day>;<volume>40</volume>(<issue>7</issue>):<fpage>968</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1086/428582</pub-id><pub-id pub-id-type="pmid">15824988</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><string-name><surname>Seung</surname>
<given-names>KJ</given-names></string-name>, <string-name><surname>Omatayo</surname>
<given-names>DB</given-names></string-name>, <string-name><surname>Keshavjee</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Furin</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Farmer</surname>
<given-names>PE</given-names></string-name>, <string-name><surname>Satti</surname>
<given-names>H</given-names></string-name>. <article-title>Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in southern Africa.</article-title>
<source>PLoS One</source>. <year>2009</year>
<month>9</month>
<day>25</day>;<volume>4</volume>(<issue>9</issue>):<fpage>e7186</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0007186</pub-id><pub-id pub-id-type="pmid">19779624</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><string-name><surname>Toczek</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Cox</surname>
<given-names>H</given-names></string-name>, <string-name><surname>du Cros</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Cooke</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ford</surname>
<given-names>N</given-names></string-name>. <article-title>Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis.</article-title>
<source>Int J Tuberc Lung Dis</source>. <year>2013</year>
<month>3</month>;<volume>17</volume>(<issue>3</issue>):<fpage>299</fpage>&#x02013;<lpage>307</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.12.0537</pub-id><pub-id pub-id-type="pmid">23211716</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Adatu</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Odeke</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Mugenyi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gargioni</surname>
<given-names>G</given-names></string-name>, <string-name><surname>McCray</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Schneider</surname>
<given-names>E</given-names></string-name>, <etal>et al.</etal>
<article-title>Implementation of the DOTS strategy for tuberculosis control in rural Kiboga district, Uganda, offering patients the option of treatment supervision in the community, 1998&#x02013;1999.</article-title>
<source>Int J Tuberc Lung Dis</source>. <year>2003</year>
<month>9</month>;<volume>7</volume>(<issue>9</issue>) <supplement>Suppl 1</supplement>:<fpage>S63</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">12971656</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Okello</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Floyd</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Adatu</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Odeke</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Gargioni</surname>
<given-names>G</given-names></string-name>. <article-title>Cost and cost-effectiveness of community-based care for tuberculosis patients in rural Uganda.</article-title>
<source>Int J Tuberc Lung Dis</source>. <year>2003</year>
<month>9</month>;<volume>7</volume>(<issue>9</issue>) <supplement>Suppl 1</supplement>:<fpage>S72</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">12971657</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Wandwalo</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Kapalata</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Egwaga</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Morkve</surname>
<given-names>O</given-names></string-name>. <article-title>Effectiveness of community-based directly observed treatment for tuberculosis in an urban setting in Tanzania: a randomised controlled trial.</article-title>
<source>Int J Tuberc Lung Dis</source>. <year>2004</year>
<month>10</month>;<volume>8</volume>(<issue>10</issue>):<fpage>1248</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">15527158</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Moher</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Liberati</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tetzlaff</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Altman</surname>
<given-names>DG</given-names></string-name>; <collab>PRISMA Group</collab>. <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.</article-title>
<source>J Clin Epidemiol</source>. <year>2009</year>
<month>10</month>;<volume>62</volume>(<issue>10</issue>):<fpage>1006</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.jclinepi.2009.06.005</pub-id><pub-id pub-id-type="pmid">19631508</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="book"><source>Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis.</source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2014</year>.</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="web">Conference abstract books [Internet]. Paris: International Union Against Tuberculosis and Lung Diseas; 2016. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.theunion.org/what-we-do/journals/ijtld/conference-abstract-books">http://www.theunion.org/what-we-do/journals/ijtld/conference-abstract-books</ext-link> [cited 2017 May 22].</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="web">OpenGrey [Internet]. Vandoeuvre-l&#x000e8;s-Nancy: Institut de l&#x02019;Information Scientifique et Technique; 2017. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.opengrey.eu/">http://www.opengrey.eu/</ext-link> [cited 2017 May 22].</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="web">Sch&#x000fc;nemann H, Bro&#x0017c;ek J, Guyatt G, Oxman A, editors. GRADE handbook. Hamilton: Evidence Prime; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html">http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html</ext-link> [cited 2017 May 22].</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><string-name><surname>Hamza</surname>
<given-names>TH</given-names></string-name>, <string-name><surname>van Houwelingen</surname>
<given-names>HC</given-names></string-name>, <string-name><surname>Stijnen</surname>
<given-names>T</given-names></string-name>. <article-title>The binomial distribution of meta-analysis was preferred to model within-study variability.</article-title>
<source>J Clin Epidemiol</source>. <year>2008</year>
<month>1</month>;<volume>61</volume>(<issue>1</issue>):<fpage>41</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.jclinepi.2007.03.016</pub-id><pub-id pub-id-type="pmid">18083461</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Higgins</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Thompson</surname>
<given-names>SG</given-names></string-name>. <article-title>Quantifying heterogeneity in a meta-analysis.</article-title>
<source>Stat Med</source>. <year>2002</year>
<month>6</month>
<day>15</day>;<volume>21</volume>(<issue>11</issue>):<fpage>1539</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1002/sim.1186</pub-id><pub-id pub-id-type="pmid">12111919</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Higgins</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Thompson</surname>
<given-names>SG</given-names></string-name>, <string-name><surname>Deeks</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Altman</surname>
<given-names>DG</given-names></string-name>. <article-title>Measuring inconsistency in meta-analyses.</article-title>
<source>BMJ</source>. <year>2003</year>
<month>9</month>
<day>6</day>;<volume>327</volume>(<issue>7414</issue>):<fpage>557</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id><pub-id pub-id-type="pmid">12958120</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><string-name><surname>Egger</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Davey Smith</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Schneider</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Minder</surname>
<given-names>C</given-names></string-name>. <article-title>Bias in meta-analysis detected by a simple, graphical test.</article-title>
<source>BMJ</source>. <year>1997</year>
<month>9</month>
<day>13</day>;<volume>315</volume>(<issue>7109</issue>):<fpage>629</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.315.7109.629</pub-id><pub-id pub-id-type="pmid">9310563</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><string-name><surname>Chan</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Yu</surname>
<given-names>MC</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>SW</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>YW</given-names></string-name>, <string-name><surname>Chien</surname>
<given-names>ST</given-names></string-name>, <etal>et al.</etal>; <collab>Taiwan Multidrug-Resistant Tuberculosis Consortium-TMTC</collab>. <article-title>Effectiveness of a government-organized and hospital-initiated treatment for multidrug-resistant tuberculosis patients&#x02013;a retrospective cohort study.</article-title>
<source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>2</issue>):<fpage>e57719</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0057719</pub-id><pub-id pub-id-type="pmid">23451263</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><string-name><surname>Cox</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Hughes</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Daniels</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Azevedo</surname>
<given-names>V</given-names></string-name>, <string-name><surname>McDermid</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Poolman</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa.</article-title>
<source>Int J Tuberc Lung Dis</source>. <year>2014</year>
<month>4</month>;<volume>18</volume>(<issue>4</issue>):<fpage>441</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.13.0742</pub-id><pub-id pub-id-type="pmid">24670700</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Gler</surname>
<given-names>MT</given-names></string-name>, <string-name><surname>Podewils</surname>
<given-names>LJ</given-names></string-name>, <string-name><surname>Munez</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Galipot</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Quelapio</surname>
<given-names>MI</given-names></string-name>, <string-name><surname>Tupasi</surname>
<given-names>TE</given-names></string-name>. <article-title>Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis.</article-title>
<source>Int J Tuberc Lung Dis</source>. <year>2012</year>
<month>7</month>;<volume>16</volume>(<issue>7</issue>):<fpage>955</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.11.0502</pub-id><pub-id pub-id-type="pmid">22584124</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Loveday</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Wallengren</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Brust</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Roberts</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Voce</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Margot</surname>
<given-names>B</given-names></string-name>, <etal>et al.</etal>
<article-title>Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa.</article-title>
<source>Int J Tuberc Lung Dis</source>. <year>2015</year>
<month>2</month>;<volume>19</volume>(<issue>2</issue>):<fpage>163</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.14.0369</pub-id><pub-id pub-id-type="pmid">25574914</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Musa</surname>
<given-names>BM</given-names></string-name>, <string-name><surname>John</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Habib</surname>
<given-names>AG</given-names></string-name>, <string-name><surname>Kuznik</surname>
<given-names>A</given-names></string-name>. <article-title>Cost-optimization in the treatment of multidrug resistant tuberculosis in Nigeria.</article-title>
<source>Trop Med Int Health</source>. <year>2016</year>
<month>2</month>;<volume>21</volume>(<issue>2</issue>):<fpage>176</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1111/tmi.12648</pub-id><pub-id pub-id-type="pmid">26610176</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Narita</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Alonso</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Lauzardo</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hollender</surname>
<given-names>ES</given-names></string-name>, <string-name><surname>Pitchenik</surname>
<given-names>AE</given-names></string-name>, <string-name><surname>Ashkin</surname>
<given-names>D</given-names></string-name>. <article-title>Treatment experience of multidrug-resistant tuberculosis in Florida, 1994&#x02013;1997.</article-title>
<source>Chest</source>. <year>2001</year>
<month>8</month>;<volume>120</volume>(<issue>2</issue>):<fpage>343</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1378/chest.120.2.343</pub-id><pub-id pub-id-type="pmid">11502627</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>Sinanovic</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Ramma</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Vassall</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Azevedo</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Wilkinson</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Ndjeka</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal>
<article-title>Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa.</article-title>
<source>Int J Tuberc Lung Dis</source>. <year>2015</year>
<month>2</month>;<volume>19</volume>(<issue>2</issue>):<fpage>172</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.14.0421</pub-id><pub-id pub-id-type="pmid">25574915</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Kerschberger</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Telnov</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mafukidze</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Cox</surname>
<given-names>H</given-names></string-name>. <article-title>Community-based MDR-TB treatment supervision is associated with improved treatment outcomes in rural Swaziland.</article-title>
<source>Int J Tuberc Lung Dis</source>. <year>2014</year>;<volume>18</volume>(<issue>11</issue>) <supplement>Suppl 1</supplement>:<fpage>S349</fpage>.</mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>Mauch</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Bonsu</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Gyapong</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Awini</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Suarez</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Marcelino</surname>
<given-names>B</given-names></string-name>, <etal>et al.</etal>
<article-title>Free tuberculosis diagnosis and treatment are not enough: patient cost evidence from three continents.</article-title>
<source>Int J Tuberc Lung Dis</source>. <year>2013</year>
<month>3</month>;<volume>17</volume>(<issue>3</issue>):<fpage>381</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.12.0368</pub-id><pub-id pub-id-type="pmid">23407227</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="web">WHO end TB strategy [Internet]. Geneva: World Health Organization; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/tb/post2015_strategy/en/">http://www.who.int/tb/post2015_strategy/en/</ext-link> [cited 2017 May 22].</mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Weiss</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Cook</surname>
<given-names>VJ</given-names></string-name>, <string-name><surname>Johnston</surname>
<given-names>JC</given-names></string-name>. <article-title>Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis.</article-title>
<source>BMC Infect Dis</source>. <year>2014</year>
<month>6</month>
<day>17</day>;<volume>14</volume>(<issue>1</issue>):<fpage>333</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2334-14-333</pub-id><pub-id pub-id-type="pmid">24938738</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><string-name><surname>Bassili</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Fitzpatrick</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Qadeer</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Fatima</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Floyd</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Jaramillo</surname>
<given-names>E</given-names></string-name>. <article-title>A systematic review of the effectiveness of hospital- and ambulatory-based management of multidrug-resistant tuberculosis.</article-title>
<source>Am J Trop Med Hyg</source>. <year>2013</year>
<month>8</month>;<volume>89</volume>(<issue>2</issue>):<fpage>271</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.13-0004</pub-id><pub-id pub-id-type="pmid">23926140</pub-id></mixed-citation></ref></ref-list></back></article>